Literature DB >> 17522145

Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy.

Satoru Kase1, Wataru Saito, Kazuhiro Ohgami, Kazuhiko Yoshida, Naoki Furudate, Akari Saito, Masahiko Yokoi, Manabu Kase, Shigeaki Ohno.   

Abstract

PURPOSE: It is widely accepted that intravitreous levels of erythropoietin (Epo) are elevated in patients with ischaemic retinal diseases such as proliferative diabetic retinopathy (PDR). The aim of this study was to examine the expression of Epo and the Epo receptor (EpoR) in epiretinal membranes with and without diabetes.
METHODS: Eighteen epiretinal membranes (PDR (n = 10), idiopathic epiretinal membranes (IERMs) without diabetes (n = 4) and inner limiting membranes (ILMs) (n = 4)) were obtained during pars plana vitrectomy. Formalin-fixed and paraffin-embedded tissues were examined by immunohistochemistry with anti-Epo and EpoR antibodies.
RESULTS: The histopathological findings demonstrated that PDR membranes consisted of a variety of endothelial cells forming a microvascular cavity with red blood cells and non-vascular stromal mononuclear cells. Membranous and cytoplasmic immunoreactivity for EpoR was strongly detected in endothelial cells and stromal cells in all PDR patients. Although microvessels were not observed in IERMs and ILMs, immunoreactivity for EpoR was noted in the cellular component of IERMs, and was weakly detected in ILMs. Epo was not expressed in any membrane.
CONCLUSION: EpoR was strongly expressed in microvessels of all PDR membranes. The in vivo evidence in this study suggests that Epo in the vitreous binds to EpoR in PDR membranes, which subsequently leads to the proliferation of new retinal vessels. EpoR immunoreactivity in non-vascular stromal cells in PDR membranes, and IERMs and ILMs might be indirectly correlated with ischaemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522145      PMCID: PMC2001006          DOI: 10.1136/bjo.2007.119404

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  20 in total

Review 1.  Important causes of visual impairment in the world today.

Authors:  Nathan G Congdon; David S Friedman; Thomas Lietman
Journal:  JAMA       Date:  2003-10-15       Impact factor: 56.272

2.  Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes.

Authors:  Ahmed M Abu El-Asrar; Luc Missotten; Karel Geboes
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

3.  Neurotrophic factor receptors in epiretinal membranes after human diabetic retinopathy.

Authors:  Takayuki Harada; Chikako Harada; Yoshinori Mitamura; Chihiro Akazawa; Kenji Ohtsuka; Shigeaki Ohno; Shinobu Takeuchi; Keiji Wada
Journal:  Diabetes Care       Date:  2002-06       Impact factor: 19.112

4.  Elevated erythropoietin in vitreous with ischemic retinal diseases.

Authors:  Yasuya Inomata; Akira Hirata; Eri Takahashi; Takahiro Kawaji; Mikiko Fukushima; Hidenobu Tanihara
Journal:  Neuroreport       Date:  2004-04-09       Impact factor: 1.837

5.  Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation.

Authors:  Makoto Sugawa; Yoko Sakurai; Yasuko Ishikawa-Ieda; Hiroshi Suzuki; Hiroaki Asou
Journal:  Neurosci Res       Date:  2002-12       Impact factor: 3.304

6.  Diabetic maculopathies.

Authors:  T S Stevens
Journal:  Int Ophthalmol Clin       Date:  1981

7.  Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease.

Authors:  Eli A Friedman; Francis A L'Esperance; Clinton D Brown; David H Berman
Journal:  Kidney Int Suppl       Date:  2003-11       Impact factor: 10.545

Review 8.  Erythropoietin: physiology and pharmacology update.

Authors:  James W Fisher
Journal:  Exp Biol Med (Maywood)       Date:  2003-01

9.  HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration.

Authors:  Christian Grimm; Andreas Wenzel; Matthias Groszer; Helmut Mayser; Mathias Seeliger; Marijana Samardzija; Christian Bauer; Max Gassmann; Charlotte E Remé
Journal:  Nat Med       Date:  2002-06-17       Impact factor: 53.440

10.  Prognostic significance of erythropoietin expression in human endometrial carcinoma.

Authors:  Geza Acs; Xiaowei Xu; Christina Chu; Peter Acs; Ajay Verma
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

View more
  10 in total

1.  Effects of erythropoietin receptor activity on angiogenesis, tubular injury, and fibrosis in acute kidney injury: a "U-shaped" relationship.

Authors:  Mingjun Shi; Brianna Flores; Peng Li; Nancy Gillings; Kathryn L McMillan; Jianfeng Ye; Lily Jun-Shen Huang; Sachdev S Sidhu; Yong-Ping Zhong; Maria T Grompe; Philip R Streeter; Orson W Moe; Ming Chang Hu
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-29

2.  Clinical and histological features of epiretinal membrane after diabetic vitrectomy.

Authors:  Yung-Ray Hsu; Chung-May Yang; Po-Ting Yeh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-15       Impact factor: 3.117

3.  Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy.

Authors:  Chuan Sun; Hongsong Zhang; Jingjing Jiang; Yuxin Li; Chuang Nie; Jianwen Gu; Ling Luo; Zhijun Wang
Journal:  Int Ophthalmol       Date:  2019-12-04       Impact factor: 2.031

4.  Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy.

Authors:  Jing Chen; Kip M Connor; Christopher M Aderman; Keirnan L Willett; Oskar P Aspegren; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-24       Impact factor: 4.799

5.  Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications.

Authors:  Zongzhong Tong; Zhenglin Yang; Shrena Patel; Haoyu Chen; Daniel Gibbs; Xian Yang; Vincent S Hau; Yuuki Kaminoh; Jennifer Harmon; Erik Pearson; Jeanette Buehler; Yuhong Chen; Baifeng Yu; Nicholas H Tinkham; Norman A Zabriskie; Jiexi Zeng; Ling Luo; Jennifer K Sun; Manvi Prakash; Rola N Hamam; Stephen Tonna; Ryan Constantine; Cecinio C Ronquillo; SriniVas Sadda; Robert L Avery; John M Brand; Nyall London; Alfred L Anduze; George L King; Paul S Bernstein; Scott Watkins; Lynn B Jorde; Dean Y Li; Lloyd Paul Aiello; Martin R Pollak; Kang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

Review 6.  Revisiting the role of erythropoietin for treatment of ocular disorders.

Authors:  S L Shirley Ding; S N Leow; R Munisvaradass; E H Koh; M L C Bastion; K Y Then; S Kumar; P L Mok
Journal:  Eye (Lond)       Date:  2016-06-10       Impact factor: 3.775

7.  Systemic and vitreous biomarkers - new insights in diabetic retinopathy.

Authors:  Bernardete Pessoa; João Heitor; Constança Coelho; Magdalena Leander; Pedro Menéres; João Figueira; Angelina Meireles; Melo Beirão
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-24       Impact factor: 3.535

8.  Full-thickness macular hole formation in proliferative diabetic retinopathy.

Authors:  Mei-Chi Tsui; Yi-Ting Hsieh; Tso-Ting Lai; Chun-Ting Lai; Hsuan-Chieh Lin; Tzyy-Chang Ho; Chang-Hao Yang; Chung-May Yang; Lu-Chun Wang
Journal:  Sci Rep       Date:  2021-12-13       Impact factor: 4.379

9.  Reduction of Laser-Induced Choroidal Neovascularization in Mice With Erythropoietin RNA Interference.

Authors:  Wenjuan Lv; Wen Chen; Shaofen Huang; Yanxuan Xu; Jia-Jian Liang; Yuqian Zheng; Shaowan Chen; Shao-Lang Chen; Tsz Kin Ng; Haoyu Chen
Journal:  Transl Vis Sci Technol       Date:  2022-08-01       Impact factor: 3.048

10.  Erythropoetin receptor expression in the human diabetic retina.

Authors:  Shaival S Shah; Stephen H Tsang; Vinit B Mahajan
Journal:  BMC Res Notes       Date:  2009-11-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.